Recently Featured

Targeted therapies to join chemo as oncology treatment backbone

March 20, 2026
Recent insights from oncology experts indicate that targeted therapies are set to become a fundamental component of cancer treatment, complementing traditional chemotherapy regimens. This shift towards combination approaches is gaining traction as evidence mounts regarding their potential to enhance patient outcomes significantly. The integration of targeted therapies into treatment protocols reflects a broader trend in…

FDA Approves Glenmark’s True Generic Version of GSK’s Flovent Inhaler

March 20, 2026
The FDA has officially approved Glenmark Pharmaceuticals’ fluticasone propionate inhalation aerosol, marking it as the first true generic version of GlaxoSmithKline’s (GSK) well-established asthma inhaler, Flovent. This approval comes after over two years during which Prasco Laboratories marketed an authorized generic version of the product, which was not a true generic but rather a branded…

After generic defense fails, Merck KGaA assumes no US Mavenclad sales after March

March 20, 2026
Germany’s Merck KGaA has announced that it anticipates no sales of its multiple sclerosis treatment Mavenclad in the U.S. after March due to an expected influx of generic competitors. This decision follows the company’s unsuccessful efforts to defend its market position against generic entrants, which is a significant shift given Mavenclad’s previous role as a…

Galderma Doubles Nemluvio Peak Sales Projection to Over $4 Billion After Strong Launch Year

March 19, 2026
Galderma has significantly increased its peak annual sales forecast for Nemluvio (nemolizumab) to exceed $4 billion, a move prompted by what CEO Flemming Ørnskov has termed an “outstanding launch trajectory” for the drug in its inaugural year. This adjustment highlights the strong market reception of Nemluvio, which is positioned as a competitor to Dupixent in…

Ongoing Cases